Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate

Intern Med. 2018 Feb 15;57(4):545-549. doi: 10.2169/internalmedicine.9036-17. Epub 2017 Dec 8.

Abstract

A 39-year-old woman was admitted to our hospital with symptoms of general fatigue, nausea, and vomiting that appeared three months after she stopped seven years of medroxyprogesterone acetate (MPA) medication for endometrial stromal sarcoma. Laboratory tests demonstrated moderate hypercalcemia. Several tests demonstrated that she was suffering from adrenal insufficiency. Glucocorticoid supplementation decreased her calcium level to a normal range, indicating that hypercalcemia was induced by adrenal insufficiency. It was suggested that she was suffering from MPA-induced adrenal insufficiency, but hypocortisolemia was being compensated by a high dose of MPA; hypocortisolemia and hypercalcemia then became evident after MPA treatment was discontinued.

Keywords: adrenal insufficiency; glucocorticoid supplementation; hypercalcemia; medroxyprogesterone acetate.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Insufficiency / complications
  • Adrenal Insufficiency / diagnosis*
  • Adult
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Female
  • Humans
  • Hypercalcemia / etiology*
  • Medroxyprogesterone Acetate / administration & dosage*
  • Withholding Treatment

Substances

  • Antineoplastic Agents, Hormonal
  • Medroxyprogesterone Acetate